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Abstract  
Context: An emergency is any medical problem that could cause death or permanent injury if not treated 
quickly. In some occasions, the kind of urgent intervention depends on patient’s exact genetic background. 
Unfortunately, the importance of genes in medical emergencies has been forgotten in recent decades.  
Evidence acquisition: In order to find relevant articles, we searched two databases of Pubmed and Embase. 
The exact words of “genes”, “genetics”, “epigenetics”, “DNA”, and “emergency” were used alone and in 
combination. All studies like randomized clinical trials (RCT), case/controls, case series, case reports, and 
review articles were studied to find the related data. No time limitation was considered for the studies.   
Results: Several aspects of genetic testing are newly considered in emergency departments including cell-free 
DNA (cfDNA) for disease diagnosis, pharmacogenetics for decreasing the adverse drug effects, and 
personalized medicine for exact emergency interventions in diseases like Vascular Ehlers-Danlos syndrome 
(vEDS). Data from genetic testing and genome wide association studies have yielded promising results to make 
medical emergency interventions more beneficial in the near future.  
Conclusion: Taking everything into consideration, several advanced genetic and epigenetic alteration 
technologies can change emergency medicine for the better. Personalized genetic data of patients can turn 
emergency medicine to personalized medicine. 
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CONTEXT  
An emergency is a medical problem that is lethal, 
life-threatening or limb-threatening if not treated 
quickly. Emergency management usually depends 
on known procedures based on most frequent 
cases and common treatment strategies, but it is 
shifting toward personalized medicine (1, 2). An 
emergency needs critical interventions to save 
patients’ life, so it is thought that genetic tests are 
not important in such situations. However, 
patient’s genetic information has just become 
considerably important even in medical 
emergencies. Through illustration, genetic 
information of newborn babies can improve 
prediction of drug-related complications as 
essentials of medical emergencies. Novel aspects of 
pharmacogenomics and genetic testing can cease 
the adverse drug reactions and subsequently 
decrease referrals to the emergency room (3). 
Genetic testing is currently used in emergency 
room for disease diagnosis through cell-free DNA 
(cfDNA), for decreasing the adverse drug effects 
through pharmacogenetics, and for exact 
emergency interventions through personalized 
medicine (4).  
Several studies have focused on the fact that 
personalized clinical protocols can increase the 
decision making quality about the individual risk 
stratification and treatment of  candidates for  
renal transplant,  patients with drug-related 
complications, and even newborn urgent 
interventions (Figure 1) (5). In this review, we 
present an overview of genetic modifications and 
the importance of genetic testing in medical 
emergencies. 
EVIDENCE ACQUISITION 
In order to find relevant articles, we searched two 
databases of Pubmed and Embase. The exact words 
of “genes”, “genetics”, “epigenetics”, “DNA”, and 
“emergency” were used alone and in combination 
with each other. All studies like randomized clinical 
trials (RCT), case/controls, case series, case 
reports, and review articles were studied to find 
the related data. No time limitation was considered 
for the studies.  
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RESULTS 
Understanding genomics, pharmacogenomics 
and personalized medicine 
Deoxyribonucleic acid (DNA) is a molecule made of 
two chains that coil around each other to form a 
double helix from the extensive sequence of triplets 
of different arrangements of four nucleotides (A; 
adenine, T; thymine, C; cytosine, and G; guanine). 
Every three nucleotides is called a codon, which is 
transcribed into RNA during the gene expression 
process (first hnRNA including introns and exons 
and then mRNA), and then mRNA is translated into 
amino acids which finally form functional proteins 
(6). Any changes in the normal sequence of DNA 
(mutation) or epigenetic changes influencing gene 
expression with no changes in the DNA sequence 
can lead to diseases (7). Genetic changes can 
happen as the single nucleotide polymorphisms 
(SNPs), which means common mutations in more 
than 1% of the population. SNPs are present all 
over the human genome, both in coding (exons) 
and noncoding (introns) regions of DNA (8). The 
Human Genome Project which aimed to sequence 
the entire human genome was completed in 2003. 
This project required 13 years, multiple research 
institutions processing samples, and $2.7 billion 
(9).  So far, about three million recorded SNPs have 
been recognized or proposed as responsible for 
different diseases. A genome-wide association 
study (GWA study, or GWAS), also known as whole 
genome association study (WGA study, or WGAS), 
was developed as an observational study of a 
genome-wide set of genetic variants in dissimilar 
persons to observe if any variant is connected with 
a trait. GWASs typically focus on associations 
between single-nucleotide polymorphisms (SNPs) 
and traits like major human diseases, but can 
equally be applied to any other genetic variants and 
any other organisms (10). The set of web-based 
SNP selection tools (freely available at 
http://www.niehs.nih.gov/snpinfo) is valid to 
analyze the linkage regions and select SNPs based 
on GWAS results, linkage disequilibrium (LD), and 
predicted functional characteristics of both coding 
and non-coding SNPs (11). Different responses of 
several patients with the same disorders to the 
same medication is under their genetic information 
like SNPs. The new concept of personalized 
medicine or precision medicine (PM) has been 
developed over the last decade so that optimal 
therapies can be chosen based on the setting of a 
patient’s genetic content or other molecular or 
cellular analyses (12, 13). Genetic information is 
main aspect of personalized medicine, that is, 
pharmacogenomics, which includes all sorts of 
personalization measures. The Pharmacogenomics 
Knowledgebase (PharmGKB) is a source of  
accurate information, and distributes information 
about the impression of human genetic variations 
(SNPs) on drug responses (14). 
Different types of genetic testing 
Genetic tests look at person's gene alterations at 
DNA sequence level as a genetic modification, at 
mRNA level (gene expression), microRNA 
expression, or variations in the quantity, role, or 
structure of key proteins coded by specific genes 
(15). Testing the DNA can be at chromosomal level, 
for DNA studies, or biochemical genetic studies. At 
chromosomal level, cytogenetics is described as the 
reading of chromosomes under the microscope. 
 
Figure 1: Flowchart of possibility of correlation between genes and emergency medicine 
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Stained chromosomes look like the ropes with 
alternative light and dark bands. An image (an 
actual photograph from one cell) of all 46 
chromosomes in their pairs is called a karyotype. 
The number and structure of the chromosomes can 
be checked and additional abnormal chromosomes 
or deletions can be detected.  Cytogenetic studies 
are possible over the blood sample, prenatal 
sample, and tissue biopsies (16, 17). Genes can be 
genetically and epigenetically studied through DNA 
analysis to examine if the DNA consensus 
sequences are correct with no changes in gene 
expression or in the alphabet of DNA. DNA 
modifications can be DNA duplications, DNA 
deletions, point mutations as nucleotides change or 
DNA repeats. Throughput techniques of DNA 
sequencing like next-generation sequencing (NGS) 
technologies and exome sequencing have recently 
made it possible to examine the whole genome and 
all exons as fast as possible (18-20). More than 
checking the DNA sequence, it is possible to 
perform protein truncation studies (considering 
protein shorter than normal size as the result of 
converting a coding trinucleotide to stop codon). 
Sometimes, a mutation in a gene yields a protein 
that is truncated and nonfunctional with abnormal 
folding and wrong 3D structure (21-23).  
Emergency tests based on DNA 
Although molecular tests do not find their exact 
position at medical emergency, there are some 
reports. For examples, biomarkers and genetic data  
in the field of infection diagnostic tests in an 
emergency medicine (24).  In patients with ≥ 2 
Systemic Inflammatory Response Syndrome (SIRS) 
principles and medical symptoms of infection at 
the emergency department of Jeroen Bosch 
Hospital, Netherlands, the amount of C-reactive 
protein (CRP), neutrophil-lymphocyte count ratio 
(NLCR), procalcitonin (PCT) and soluble urokinase 
plasminogen activator receptor (suPAR) were 
evaluated. For this purpose, 1 ml EDTA blood was 
collected and selective pathogen DNA isolation was 
performed with MolYsis (Molzym). In fact, Van den 
Brule and his colleagues suggested that molecular 
assays NLCR is a cheap, fast, easy to define 
biomarker for  pathogen identification using 
molecular diagnostics (24). There is another report 
on the plasma nuclear and mitochondrial DNA 
(mtDNA) quantity as the  forecasters of outcome in 
patients with severe sepsis in the emergency room 
in Taiwan (25). Sepsis is the presence of dangerous 
microorganisms in patients’ blood or other tissues 
and the body’s response to their presence, 
potentially leading to the malfunctioning of various 
organs, shock, and death (26).  Despite the 
development of clinical practice guidelines in a 
several areas related to infections and sepsis, the 
rate of death from sepsis is still high (27, 28). Kung 
and colleagues designed the prognostic importance 
of circulating plasma DNA levels in patients with 
severe sepsis. They studied over 67 patients to 
determine their plasma DNA levels by real-time 
quantitative polymerase chain reaction assay (RT-
PCR). They suggested the level of plasma 
mitochondrial DNA as a more potent predictor than 
lactate concentration or sequential organ failure 
assessment (SOFA) score on admission. Vascular 
Ehlers-Danlos syndrome (vEDS) is a disease with 
arterial, intestinal, and/or uterine fragility, thin 
and translucent skin, and easy bruising (29). More 
often than not, vEDS patients are trained to apply 
urgent medical attention for sudden, unexplained 
pain. They can be under medical or surgical 
management for arterial complications, bowel 
rupture, or uterine rupture during pregnancy. It is 
diagnosed in relatives by documentation of a 
heterozygous pathogenic variant in COL3A1 gene 
(Collagen Type III Alpha 1 Chain) (30, 31). 
Depending on the disease, taking the right kind of 
emergency measure may result in life or death.  For 
vEDS, due to the complicated disease signs, 
emergency interventions can simply move in the 
wrong way. So it is suggested that patients provide 
related genetic testing information to the 
emergency physician.  
Cell-free plasma DNA in medical emergency 
Cell-free DNA (cfDNA) is a short fragment of DNA 
(about 200 nucleotides) released from dead cells 
following necrosis or apoptosis. Actually, cfDNA 
are representative of genetic and epigenetic nature 
of cells and a perfect non-invasive tool for real-time 
analysis of the body especially in malignancies (32-
34). Both quantitative and mutation cfDNA can 
provide essential information about diseases and 
require digital droplet PCR (ddPCR) and ultra-deep 
sequencing technology (35, 36). This new 
technique is usually applied for cfDNA 
characterizations with outstanding sensitivity and 
specificity. Contrary to NGS that is linked to high 
error rates in cfDNA (error rates range roughly 
from 0.1% to 1%) (37, 38). For cfDNA analysis, the  
incorporation of unique identifiers (UIDs) during 
library preparation is recommended (39, 40). 
Recently, some benefits of cfDNA have been 
suggested for medical emergency. Fever (pyrexia) 
up to 103 °F (39.4 °C) is not an emergency in adults, 
but is a sign of infection in infants, and on 
occasions, it can be an indicator of other underlying 
diseases like immune-mediated and neoplastic 
conditions in adult, as well. Srugo et al. issued  the 
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novel tool for discrimination of bacterial and viral 
infections in children at five pediatric emergency 
departments (41). They suggested that this novel 
assay was considerably more precise than CRP, 
procalcitonin, and routine laboratory parameters. 
Additionally, a systematic review and meta-
analysis by Hoeboer et. al. investigated the 
diagnostic accuracy of PCT for bacteremia (42). In 
emergency cases, the normal concentrations of 
cfDNA can eliminate the presence of an infection in 
febrile patients while high concentrations of cfDNA 
and its increase to ten times indicate severity of 
infections (43). Both quick Sequential Organ 
Failure Assessment (qSOFA) score and cfDNA are 
prognostic markers in patients with infection (44). 
Jackson Chornenki and his colleagues showed that 
the origin and mechanism of release of cfDNA 
change in patients with trauma and sepsis (45). In 
sepsis, cfDNA is possibly released by activated 
neutrophils through the process of NETosis, while 
cfDNA is released from injured or necrotic cells and 
does not seem to have prognostic value in trauma 
patients. 
Personalized medicine and pharmacogenomics 
in medical emergency  
Adverse drug events happened in 13.5 million 
outpatient and emergency department visits over a 
recent 3-year period, with older adults as mainly 
vulnerable (46). The new knowledge of 
pharmacogenetics has considerably impacted the 
progress in identifying genetic risk factors for 
idiosyncratic adverse drug reactions over the last 
three decades (47). Pharmacogenetics and 
pharmacogenomics have been extensively known 
as central steps of personalized medicine because 
they consider the genetic information to aim at the 
best treatment strategy for each patient. 
Personalized medicine is a medical model that 
divides people into different subgroups regarding 
their genetic map for medical interventions. 
However, not many written documents exist 
regarding how personalized medicine can change 
emergency care. It can be expected that recent 
breakthrough in genetic testing techniques can 
lead to characterizing patients in completely 
individualized diagnosis and treatment (48). The 
rational and careful use of pharmacogenetics can 
improve drug choice by increasing the 
effectiveness and lessen harmful side effects. A 
report by Elliott in polypharmacy patients under 
home health management indicated that 
pharmacogenetic testing joined guidance to form a 
clinical decision support tool (CDST) on reducing 
drug, gene, and cumulative interaction risk, and it 
can offer noteworthy insights in prescription drug 
treatment and decreasing re-hospitalization and 
emergency department visits (49).  
DISCUSSION  
The new advanced techniques in genetic variations 
and polymorphism studies together with 
epigenetic studies have resulted in WGAS and 
EWAS. They improve the knowledge of disease 
precision medicine and prediction of medication 
efficacy in different patients. Pharmacogenetics is 
the exact knowledge of making a bridge between 
genetic and drug efficacy, side effects, and 
complications regarding each person’s genetic 
information and is recently considered in 
emergency medicals. The new techniques of 
sequencing like NGS, exome sequencing, 
methylation specific sequencing, and ddPCR make 
it possible to have huge genetic and epigenetic 
information that can be used in emergency room. 
Recent discovery of cfDNA can help clinicians to 
make more accurate decision for inflammatory 
diseases, stroke, and cancers. However, 
optimization of emergency medicine based on 
patient’s genetic and epigenetic details need time. 
Recent advances in molecular biology will soon 
bring the personalized emergency medicine into 
the practice. In Systemic Inflammatory Response 
Syndrome (SIRS), mitochondrial DNA in sepsis, 
Vascular Ehlers-Danlos syndrome (vEDS) based on 
variant in COL3A1 gene are pacemaker in this way. 
CONCLUSIONS 
Taking everything into consideration, several 
advanced genetic and epigenetic alteration 
technologies can change emergency medicine for 
the better. Personalized genetic data of patients can 
turn emergency medicine to personalized 
medicine.  
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